Annual report pursuant to Section 13 and 15(d)

Segment, Geographical and Other Revenue Information (Tables)

v3.20.4
Segment, Geographical and Other Revenue Information (Tables)
12 Months Ended
Dec. 31, 2020
Segment Reporting [Abstract]  
Schedule of Segment Reporting
The following tables provide financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):

Year Ended December 31, 2020 Year Ended December 31, 2019
Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total
Revenues:
Product revenue $ 30,220  $ —  $ 30,220  $ 29,465  $ —  $ 29,465 
Research and development revenue 17,886  20,950  38,836  28,691  10,302  38,993 
Total revenues 48,106  20,950  69,056  58,156  10,302  68,458 
Costs and operating expenses:
Cost of product revenue 13,742  —  13,742  15,632  —  15,632 
Research and development (1)
20,923  21,705  42,628  19,380  13,278  32,658 
Selling, general and administrative(1)
9,597  2,355  11,952  8,462  2,222  10,684 
Total segment costs and operating expenses 44,262  24,060  68,322  43,474  15,500  58,974 
Income (loss) from operations $ 3,844  $ (3,110) 734  $ 14,682  $ (5,198) 9,484 
Corporate costs (2)
(22,306) (19,624)
Depreciation and amortization (2,099) (1,778)
Loss before income taxes $ (23,671) $ (11,918)
(1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases.
(2) Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.
Year Ended December 31, 2019 Year Ended December 31, 2018
Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total
Revenues:
Product revenue $ 29,465  $ —  $ 29,465  $ 25,590  $ —  $ 25,590 
Research and development revenue 28,691  10,302  38,993  21,483  13,521  35,004 
Total revenues 58,156  10,302  68,458  47,073  13,521  60,594 
Costs and operating expenses:
Cost of product revenue 15,632  —  15,632  12,620  —  12,620 
Research and development (1)
19,380  13,278  32,658  18,924  10,185  29,109 
Selling, general and administrative(1)
8,462  2,222  10,684  7,538  771  8,309 
Total segment costs and operating expenses 43,474  15,500  58,974  39,082  10,956  50,038 
Income (loss) from operations $ 14,682  $ (5,198) 9,484  $ 7,991  $ 2,565  10,556 
Corporate costs (2)
(19,624) (20,324)
Depreciation (1,778) (1,147)
Loss before income taxes $ (11,918) $ (10,915)
(1) For the year ended December 31, 2019, research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases. For the year ended December 31, 2018, research and development expenses and selling, general and administrative expenses exclude depreciation.
(2) Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.
The following table provides stock-based compensation expense included in income (loss) from operations (in thousands):
Years Ended December 31,
2020 2019 2018
Performance Enzymes $ 2,970  $ 2,303  $ 2,591 
Novel Biotherapeutics 768  695  338 
Corporate cost 3,990  3,945  4,960 
Total $ 7,728  $ 6,943  $ 7,889 
Schedule of Customers That Contributed 10% or More of Total Accounts Receivable
Customers that each accounted for 10% or more of our total revenues were as follows:
Percentage of Total Revenues
For the Years Ended December 31,
  2020 2019 2018
Merck 26  % 28  % 29  %
Nestlé Health Science 11  % 15  % 22  %
Novartis * 23  % *
Tate & Lyle * * 13  %
Takeda Pharmaceutical Co. Ltd. 19  % * *
* Percentage was less than 10%
Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows:
 
Percentage of Accounts Receivables
As Of December 31,
  2020 2019
Merck & Co. 32  % 38  %
Nestlé Health Science 13  % 10  %
Novartis 25  % *
* Percentage was less than 10%
Schedule of Revenues by Geographical Area
Geographic revenues are identified by the location of the customer and consist of the following (in thousands):
  Year Ended December 31, 2020
2020 2019 2018
Revenues
Americas $ 24,352  $ 13,039  $ 15,370 
EMEA 19,257  37,133  22,361 
APAC 25,447  18,286  22,863 
Total revenues $ 69,056  $ 68,458  $ 60,594 
Schedule of Long-lived Assets by Geographical Area
Identifiable long-lived assets by location was as follows (in thousands):
  December 31,
  2020 2019
United States $ 31,176  $ 30,387 
Schedule of Intangible Assets and Goodwill
Identifiable goodwill was as follows (in thousands):`
Year Ended December 31, 2020 Year Ended December 31, 2019
Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total
Goodwill $ 2,463  $ 778  $ 3,241  $ 2,463  $ 778  $ 3,241